NGNE posts Q2 2025 earnings release and updated corporate presentation

Rhea-AI Filing Summary

On August 11, 2025, Neurogene Inc. reported that it issued a press release announcing financial results for the quarter ended June 30, 2025 and posted an updated corporate presentation on its website. The Form 8-K attaches Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation) and states these exhibits are being furnished, not filed, so they are not subject to Section 18 liabilities or deemed incorporated by reference. The filing text does not include the actual earnings figures; the report is signed by Christine Mikail, President and Chief Financial Officer.

Positive

• Issued a press release announcing quarterly results for the quarter ended June 30, 2025
• Posted an updated corporate presentation and attached both documents as Exhibits 99.1 and 99.2

Negative

• None.

Insights

Financial Analyst

TL;DR: Neurogene furnished its Q2 2025 results press release and an updated presentation; the 8-K itself contains no financial figures, so direct investor implications are limited.

The filing notifies investors that the company announced quarterly results and uploaded a corporate presentation, but it does not embed the earnings metrics in the 8-K text. For market impact, the attached press release and presentation (Exhibits 99.1 and 99.2) contain the material details investors will need to assess performance. The 8-K functions mainly as formal notice of those disclosures; absent the exhibits' content here, the filing is procedural rather than informative about results.

Corporate Governance Expert

TL;DR: Exhibits are explicitly "furnished, not filed," which limits legal incorporation and Section 18 liability; the report follows routine disclosure practice.

The 8-K clearly states Exhibits 99.1 and 99.2 are furnished and therefore are not subject to Section 18 liability or automatically incorporated into other Exchange Act or Securities Act filings. That designation is important for legal posture and limits statutory liability for the content of those exhibits within this filing. The report is signed by the company CFO, reflecting standard internal authorization for such disclosures.

0001404644FALSE00014046442024-03-182024-03-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2025

Neurogene Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-36327			98-0542593
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)

535 W 24th Street, 5th Floor

New York, NY 10011

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (877) 237-5020

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.000001 par value

NGNE

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On August 11, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release dated August 11, 2025
99.2						Corporate Presentation (August 11, 2025)
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			NEUROGENE INC.
Date: August 11, 2025			By:			/s/ Christine Mikail
						Name: Christine Mikail
						Title: President, Chief Financial Officer

FAQ

What did Neurogene (NGNE) disclose in this Form 8-K?

Neurogene announced it issued a press release with financial results for the quarter ended June 30, 2025 and posted an updated corporate presentation; these are attached as Exhibits 99.1 and 99.2.

Does the 8-K include the actual Q2 2025 financial figures?

No. The 8-K states the company issued a press release announcing results but the filing text does not include the earnings figures themselves.

Where can I find the press release and presentation referenced in the 8-K?

The documents are furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation) to this Current Report and were posted on the company's website.

Are the attached exhibits considered "filed" under the Exchange Act?

No. The filing explicitly states Exhibits 99.1 and 99.2 are furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Who signed the Form 8-K for Neurogene?

The Form 8-K was signed by Christine Mikail, President and Chief Financial Officer, dated August 11, 2025.